GM1 drug added to clot removal for acute stroke
Part of Brain & nervous system, Heart & circulation clinical trials.
This study tests whether adding a medicine called GM1 to emergency clot-removal surgery helps people recover better from sudden strokes caused by blood clots in major brain arteries. GM1 may protect brain cells from damage during and after the stroke.
Summary written for real people, not researchers, by Clin2.
Who can take part
- Age 18–80 years old
- Had a sudden stroke caused by a blood clot in a major brain artery (confirmed by imaging)
- Admitted within 24 hours of stroke symptoms starting
- Stroke severity score (NIHSS) of 6 or higher at hospital arrival
- Brain scan shows at least 3% viable brain tissue remaining (ASPECTS ≥3)
- Able to return for follow-up visits for 90 days after the stroke
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a surgical rescue treatment for people who have had a major stroke from a large artery blockage, but the standard clot removal procedure (thrombectomy) did not fully open the artery. The goal is to see if combining surgery with the earlier procedure can improve outcomes.
This trial tests whether giving a clot-dissolving medication directly into the brain's blood vessels during a standard procedure (mechanical thrombectomy) can improve outcomes for people with a stroke caused by a blockage in a medium-sized artery. It may be an option for patients who arrive at the hospital within 24 hours of symptom onset and have enough salvageable brain tissue.
This study tests whether a medication called a GLP-1 receptor agonist (a type of drug used for diabetes) can improve recovery after a major stroke that was treated with a procedure to remove the blood clot. The goal is to see if this drug helps reduce further brain damage and improve outcomes.
This trial tests if removing a large blood clot from the brain up to 3 days after a stroke improves recovery compared to standard medical care alone. It is for patients who have a severe stroke and are otherwise healthy enough for the procedure.
This trial tests whether giving a clot-busting medication (tenecteplase) directly into the artery after an incomplete clot-removal procedure can improve blood flow and outcomes in people with large vessel strokes. It aims to help those who had partial reopening after mechanical thrombectomy.
This study tests whether adding a drug called human urinary kallidinogenase to standard clot-removal therapy helps people recover better after a large-vessel stroke. If you qualify, you would receive the drug or a placebo by IV along with the procedure, and doctors will monitor your recovery.
Hear when a new Stroke trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.